A randomised trial to compare the effectiveness of two antidepressants (escitalopram, a selective serotonin re-uptake inhibitor, SSRI) and (nortriptyline, a tricyclic antidepressant, TCA) compared to placebo for the treatment of depression in patients with Parkinson's disease

Submission date	Recruitment status No longer recruiting	[X] Prospectively registered		
15/02/2019		[X] Protocol		
Registration date	ce Overall study status Completed Condition category Mental and Behavioural Disorders	Statistical analysis plan		
22/02/2019		Results		
Last Edited		Individual participant data		
27/04/2023		Record updated in last year		

Plain English summary of protocol

Background and study aims

Parkinson's disease is a progressive neurological disorder that leads to increasing disability and functional decline. Currently, psychological therapies are used to treat depression in Parkinson's disease but often antidepressant medications are also required. The most commonly used antidepressants in the UK are selective serotonin re-uptake inhibitors (SSRIs) and tricyclic antidepressants (TCA) which are used in millions of people to treat clinical depression. There is currently no conclusive evidence on the appropriate choice of antidepressants in Parkinson's disease. There is some trial evidence that SSRIs, such as escitalopram, can be used cautiously to treat depression in Parkinson's disease but cases of worsening of parkinsonism have been reported along with other side effects including an increase in falls. The TCA nortriptyline can have a beneficial effect on parkinsonian features, such as tremor in early Parkinson's disease, and some trial evidence has shown that TCAs are effective in the treatment of depressive symptoms in Parkinson's disease. However, TCAs are currently only recommended as a treatment for depression in Parkinson's disease if a patient was unable to tolerate the SSRI, due to their increased risk of side effects. Nortriptyline has also been suggested in laboratory studies to reduce the physical and mental changes in Parkinson's disease, but there is not yet any information from clinical trials to support this. If a patient wants to know more about depression associated with Parkinson's disease, they can talk to the doctor or nurse who is treating them. The aim of this study is to find out if the antidepressants escitalopram and nortriptyline are effective in the treatment of depression in patients with Parkinson's disease and their effect on slowing down the development of the movement symptoms associated with Parkinson's disease.

Who can participate?

Patients aged 18 years or abve with a confirmed diagnosis of Parkinson's disease and who have been experiencing depressive symptoms

What does the study involve?

Patients are randomly assigned to one of the two drugs (escitalopram or nortriptyline) or a placebo (dummy drug) and followed up for one year. Patients attend five trial appointments over a 12-month period. Throughout the trial they receive four deliveries in the post containing the trial treatment. They need to be at home when the medication is sent to them and the research staff at the hospital/neurology centre liaise with them beforehand to ensure that they are available for the delivery. Each time the trial medication is sent to them, they receive a phone call from a member of the research team to confirm that they have received it. At each trial visit, they are asked to complete a number of trial assessments including questionnaires. These questionnaires contain questions asking about depressive symptoms, anxiety and movement symptoms. There are also general questions asking about quality of life. Their doctor completes some questionnaires also asking about the patient's movement skills and their mental capabilities. If they have a carer, they are asked to complete two questionnaires which provide information on their quality of life and responsibilities.

What are the possible benefits and risks of participating?

If a patient is randomised to receive escitalopram or nortriptyline, this may help to treat their depression. They have a two in three chance of receiving either of the two antidepressants and a one in three chance of receiving placebo. Although there is no promise that this trial will benefit them personally, the results generated may help to improve the treatment options of people with depression in Parkinson's disease in the future. There are some medications that can cause serious side effects when taken with the trial medications. For patients' safety, they are aksed to tell the trial doctor about all medications they are taking before and during the trial. This includes other prescribed medicines, over the counter medicines, recreational drugs, herbal medicines or supplements. If they suffer any unpleasant effects or have any concerns regarding their health at any point during the trial, they will be told to tell their trial doctor or nurse. They may be asked to attend the clinic for an additional visit(s) for further examination or tests. The active trial drugs may pose unknown risks to a pregnant woman, an unborn baby, or a breastfeeding child. As such, pregnant women are not allowed to take part in this trial. Urine samples from female participants of child bearing potential will be tested at visits 1, 2, 3 and 4 to make sure they are not pregnant and patients will be advised to use adequate contraception for the duration of the trial. This trial includes an optional sub-study which requires a blood sample to be taken at visit 1. Taking blood can be uncomfortable, but rarely results in any serious problems. Reported side effects include feeling light-headed or faint, bruising and/or discomfort at the site of injection. All reasonable efforts are made to make this trial safe. Despite this, some risks might not be possible to predict. New information about the treatment being studied may become available while the trial is running. The patients will be told about any new findings that might affect whether they want to continue in the trial.

Where is the study run from? University College London (UK)

When is the study starting and how long is it expected to run for? June 2018 to April 2023

Who is funding the study? National Institute for Health Research (NIHR) Health Technology Assessment (HTA) programme (UK)

Who is the main contact? Trial Manager, adept@ucl.ac.uk

Contact information

Type(s)

Scientific

Contact name

Dr Helen Knowles

Contact details

Comprehensive Clinical Trials Unit at UCL
Institute of Clinical Trials and Methodology
UCL
Gower Street
London
United Kingdom
WC1E 6BT
+44 (0)203 108 7878
adept@ucl.ac.uk

Additional identifiers

Protocol serial number

39448; HTA 16/145/01

Study information

Scientific Title

A randomised placebo-controlled trial on the effectiveness of escitalopram and nortriptyline for depressive symptoms in Parkinson's disease.

Substudy on the effectiveness of nortriptyline to delay motor progression in Parkinson's disease with depressive symptoms compared to placebo.

Acronym

ADepT-PD

Study objectives

Based on the previous evidence from small trials, the hypothesis is that both SSRIs and TCAs are effective compared to placebo and the difference in efficacy between TCAs and SSRIs is likely to be small, but that the tolerability of SSRIs is higher in this population than that of TCA due to the rate of adverse effects.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Approved 15/03/2019, London-Riverside REC (Level 3 Block B, Whitefriars, Lewins Mead, Bristol, BS1 2NT; +44 (0)207104 8204; nrescommittee.london-riverside@nhs.net) ref: 19/LO/0288

Study design

Multicentre double-blind randomized placebo-controlled trial

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Depression in patients with Parkinson's disease

Interventions

Current interventions as of 27/04/2023:

Method of randomisation: Stratified randomisation will be performed with strata defined by site and depression severity (BDI-II 0-19/20-63).

Patients will be randomly assigned to one of the two drugs or a placebo and followed up for one year.

Escitalopram target dose:

- 1. 65 years and under: starting dose 1 tablet daily (5 mg). Thereafter, dosage will be increased by one tablet per day, at two-weekly intervals, to a maximum of four tablets (20 mg) per day.
- 2. Over 65 years and/or those with hepatic impairment: starting dose 1 tablet daily (5 mg). Thereafter, dosage will be increased by one tablet per day, at two-weekly intervals, to a maximum of two tablets (10 mg) per day.

Nortriptyline target dose:

1. 65 years and under: starting dose 1 tablet daily (25 mg). Thereafter, dosage will be increased by one tablet per day, at two-weekly intervals, to a maximum of four tablets (100 mg) per day. 2. Over 65 years and/or those with hepatic impairment: starting dose 1 tablet daily (25 mg). Thereafter, the escitalopram dosage will be increased by one tablet per day, at two-weekly intervals, to a maximum of two tablets (50 mg) per day.

Total duration of treatment (all arms): All patients will receive trial medication for between 54 and 58 weeks.

Previous interventions:

Method of randomisation: Stratified randomisation will be performed with strata defined by site and depression severity (BDI-II 0-19/20-63).

Patients will be randomly assigned to one of the two drugs or a placebo and followed up for one year.

Escitalopram target dose:

- 1. 65 years and under: starting dose 1 tablet daily (5 mg). Thereafter, dosage will be increased by one tablet per day, at two-weekly intervals, to a maximum of four tablets (20 mg) per day.
- 2. Over 65 years and those with hepatic impairment: starting dose 1 tablet daily (5 mg). Thereafter, dosage will be increased by one tablet per day, at two-weekly intervals, to a maximum of two tablets (10 mg) per day.

Nortriptyline target dose:

1. 65 years and under: starting dose 1 tablet daily (25 mg). Thereafter, dosage will be increased by one tablet per day, at two-weekly intervals, to a maximum of four tablets (100 mg) per day. 2. Over 65 years and those with hepatic impairment: starting dose 1 tablet daily (25 mg). Thereafter, the escitalopram dosage will be increased by one tablet per day, at two-weekly

intervals, to a maximum of two tablets (50 mg) per day.

Total duration of treatment (all arms): All patients will receive trial medication for between 53 and 56 weeks.

Intervention Type

Drug

Phase

Phase III

Drug/device/biological/vaccine name(s)

Escitalopram, nortriptyline

Primary outcome(s)

Depressive symptoms measured using the Beck Depression Inventory (BDI-II) at 8 weeks of treatment

Key secondary outcome(s))

Measured at 8, 26 and 52 weeks of treatment:

Patient-reported outcomes:

- 1. Level of depression measured using the Becks Depression Inventory (BDI-II) at weeks 26 and 52
- 2. Level of depression measured using the Patient Health Questionnaire (PHQ9)
- 3. Number of participants experiencing side effects (adverse reactions) on the Modified Toronto Side Effects Scale and reporting of other adverse events
- 4. Anxiety symptoms measured using the Parkinson Anxiety Scale
- 5. Quality of life measured using the EQ-5D-5L questionnaire
- 6. Capability measured using the ICECAP-O questionnaire
- 7. Health and social care resource use measured using the modified Client Service Receipt Inventory (CSRI)
- 8. Time spent by paid carers measured using a modified version of the iMTA Valuation of Informal Carers Questionnaire (iVICQ) (asked alongside the CSRI)
- 9. Changes in concomitant medication

Clinician and patient-reported outcomes:

1. Motor and non-motor experiences measured using the MDS-UPDRS69 Part I and II, and motor examination and motor complications measured using the MDS-UPDRS Part III and IV (including a recording of the participant's movements)

Clinician-reported outcomes:

- 1. Cognitive function measured using the Montreal Cognitive Assessment (MoCA)
- 2. Overall clinical effectiveness measured using the Global Clinical Impression scale (CGI) change in health question
- 3. Levodopa-equivalence dose
- 4. Number of drop-outs

Carer-reported outcomes:

The trial does not require that the participants have a carer, however, if a participant does have a carer, the carer will be asked if they agree to complete the following questionnaires:

- 1. Carer's quality of life measured using the EQ-5D-5L63-64 and Carers Quality of Life Questionnaire for Parkinsonism
- 2. Impact on informal carers measured using a modified version of the iVICQ68 (asked alongside the CSRI)

Completion date

30/04/2023

Eligibility

Key inclusion criteria

Current inclusion criteria as of 27/04/2023:

- 1. Patients with a diagnosis of idiopathic PD, based on a history and neurological exam performed by the enrolling investigator with presence of at least two of the three cardinal signs of PD: rigidity, bradykinesia, and rest tremor with no evidence of diagnostic alternatives.
- 2. Aged 18 years old or above
- 3. Fulfilling operationally defined subsyndromal depression (presence of two or more depressive symptoms at threshold or subthreshold levels, at least one of which had to include depressed mood or anhedonia or diagnostic (DSM-V) criteria for a depressive disorder (i.e. major depressive disorder or persistent depressive disorder)).
- 4. Beck Depression Inventory-II (BDI-II) score ≥14.
- 5. Written informed consent provided.
- 6. Treatment with antiparkinsonian medication is optimised or stable for at least 4 weeks before date of randomisation and there are no plans to change up to primary endpoint (8 weeks).

Previous inclusion criteria:

- 1. Patients with a diagnosis of idiopathic PD, based on a history and neurological exam performed by the enrolling investigator with presence of at least two of the three cardinal signs of PD: rigidity, bradykinesia, and rest tremor with no evidence of diagnostic alternatives
- 2. Aged 18 to 85 years
- 3. Fulfilling diagnostic (DSM-V) criteria for a depressive disorder (i.e., major depressive disorder or persistent depressive disorder) or operationally defined subsyndromal depression (presence

of two or more depressive symptoms at threshold or subthreshold levels, at least one of which has to include depressed mood or anhedonia

4. Beck Depression Inventory-II (BDI-II) score > = 14 5. Written informed consent provided

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

18 years

Sex

All

Total final enrolment

52

Key exclusion criteria

Current exclusion criteria as of 27/04/2023:

- 1. Women who are pregnant, breastfeeding or of childbearing potential without effective contraception (hormonal or barrier method of birth control; or abstinence). Periodic abstinence (e.g.calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception.
- 2. Patients who do not have sufficient understanding of the English language to be or are not able to understand the Patient Information Sheet or the self-completed questionnaires or patients who are unable to communicate answers to the self-rating questionnaires.
- 3. Patients with Montreal Cognitive Assessment (MoCA) score <16 or without capacity to consent.
- 4. Treatment with an antidepressant within 4 weeks of enrolment (except for a small dose of amitriptyline up to 30 mg for indications other than depression).
- 5. Patients with known severe liver failure.
- 6. Absolute contraindications to escitalopram or nortriptyline. These include:
- a. Patients with known QT-interval prolongation 57 or congenital long QT syndrome.
- b. Recent myocardial infarction (<3 months), any degree of heart block or other cardiac arrhythmias precluding treatment with nortriptyline or escitalopram according to clinical judgement.
- 7. Medications contraindicated on nortriptyline or escitalopram. These include:
- a. Non-selective and selective irreversible monoamine oxidase inhibitors (MAOIs) within 14 days. However, the antiparkinsonian selective reversible MAO-B inhibitors rasagiline, selegiline and safinamide are not contraindicated.
- b. Concomitant QT prolonging drugs, including domperidone, apomorphine at high doses (single dose or hourly rate of >6mg), certain neuroleptics (not quetiapine or clozapine), quinine, class IA and III antiarrhythmics (amiodarone, dronedarone and disopryamide), the antihistamines astemizole, mizolastine, the antimicrobial agents sparfloxacin, moxifloxacin, erythromycin IV, pentamidine, anti-malarian treatment), and some antiretrovirals.

- 8. Patients indicating active suicidal ideation or intent on the BDI-II item 9 and who, after clinical review of risk using the standardised Suicide Risk Management Protocol, need to be referred for immediate treatment.
- 9. Participation in another clinical trial of an investigational medicinal product or device within the last 30 days of randomisation.
- 10. Any clinical condition which in the opinion/ clinical judgement of the investigator would make the patient unsuitable for the trial due to safety concerns.

Previous exclusion criteria:

- 1. Women who are pregnant, breastfeeding or of childbearing potential without effective contraception (hormonal or barrier method of birth control; or abstinence)
- 2. Patients who do not have sufficient understanding of the English language to be able to read and understand the self-completed questionnaires or patients who are unable to communicate answers to the self-rating questionnaires
- 3. Patients with Montreal Cognitive Assessment (MoCA) score < 16 or without capacity to consent
- 4. Treatment with an antidepressant within 4 weeks of enrolment (except for a small dose of amitriptyline up to 50 mg for indications other than depression)
- 5. Absolute contraindications to escitalopram or nortriptyline. These include: a. Patients with known QT-interval prolongation or congenital long QT syndrome. b. Recent myocardial infarction, any degree of heart block or other cardiac arrhythmias
- 6. Medications contraindicated on nortriptyline or escitalopram. These include: a. Non-selective and selective irreversible monoamine oxidase inhibitors (MAOIs) within 14 days. However, the antiparkinsonian selective reversible MAO-B inhibitors rasagiline, selegiline and safinamide are not contraindicated b. Concomitant QT prolonging drugs, including domperidone, apomorphine at high doses (single dose or hourly rate of > 6mg), certain neuroleptics (not quetiapine or clozapine), quinine, class IA and III antiarrhythmics (amiodarone, dronedarone and disopryamide), the antihistamines astemizole, mizolastine, the antimicrobial agents sparfloxacin, moxifloxacin, erythromycin IV, pentamidine, anti-malarian treatment),and some antiretrovirals 7. Patients indicating active suicidal ideation or intent on the BDI-II item 9 and who, after clinical review of risk using the standardised Suicide Risk Management Protocol, need to be referred for immediate treatment
- 8. Treatment with antiparkinsonian medication should be optimized and stable within 4 weeks of receiving the trial medication and with no plans to change up to primary endpoint (8 weeks) 9. Enrolment in another clinical trial of an investigational medicinal product or device within the last 30 days

Date of first enrolment 30/11/2020

Date of final enrolment 09/11/2022

Locations

Countries of recruitment United Kingdom

England

Study participating centre Royal Free London NHS Foundation Trust

Royal Free Hospital Pond Street London United Kingdom NW3 2QG

Study participating centre Lewisham and Greenwich NHS Trust

University Hospital Lewisham Lewisham High Street London United Kingdom SE13 6LH

Study participating centre Luton and Dunstable University Hospital

Lewsey Road Luton United Kingdom LU4 0DZ

Study participating centre Northumbria Healthcare NHS Foundation Trust

North Tyneside General Hospital Rake Lane North Shields United Kingdom NE29 8NH

Study participating centre John Radcliffe Hospital

Headley Way Headington Oxford United Kingdom OX3 9DU

Study participating centre Christchurch Hospital, University Hospitals Dorset

Christchurch Hospital Fairmile Road Christchurch United Kingdom BH23 2JX

Study participating centre St Peters Hospital

Guildford Road Chertsey United Kingdom KT16 0PZ

Study participating centre Royal Cornwall Hospitals NHS Trust

Royal Cornwall Hospital Treliske Truro United Kingdom TR1 3LJ

Study participating centre Cornwall Partnership NHS Foundation Trust

Carew House Beacon Technology Park Dunmere Road Bodmin United Kingdom PL31 2QN

Study participating centre NIHR Newcastle Clinical Ageing Research Unit (CARU)

Freeman Hospital Freeman Road High Heaton Newcastle upon Tyne United Kingdom NE7 7DN

Study participating centre National Hospital for Neurology & Neurosurgery

Queen Square London United Kingdom WC1N 3BG

Study participating centre Yeovil District Hospital NHS Foundation Trust

Higher Kingston Yeovil United Kingdom BA21 4AT

Study participating centre Addenbrookes

Addenbrookes Hospital Hills Road Cambridge United Kingdom CB2 0QQ

Study participating centre Charing Cross Hospital

Fulham Palace Road London United Kingdom W6 8RF

Study participating centre Livewell Southwest

Local Care Centre 200 Mount Gould Road Plymouth United Kingdom PL4 7PY

Study participating centre Sheffield Teaching Hospitals NHS Foundation Trust

Royal Hallamshire Hospital

Glossop Road Sheffield United Kingdom S10 2JF

Sponsor information

Organisation

University College London

ROR

https://ror.org/02jx3x895

Funder(s)

Funder type

Government

Funder Name

NIHR Evaluation, Trials and Studies Co-ordinating Centre (NETSCC); Grant Codes: 16/145/01

Results and Publications

Individual participant data (IPD) sharing plan

The datasets generated during and/or analysed during the current study are/will be available upon request from Prof. Anette Schrag (adept@ucl.ac.uk), after formal discussion/application to the Trial Steering Committee (TSC), consent will be obtained from participants, and only anonymised data will be available.

IPD sharing plan summary

Available on request

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<u>Protocol article</u>		12/12/2022	27/04/2023	Yes	No
HRA research summary			28/06/2023	No	No
Participant information sheet	Participant information sheet	11/11/2025	11/11/2025	No	Yes
Study website	Study website	11/11/2025	11/11/2025	No	Yes